News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Evolutec Ltd To Stop Investing In rEV131 As Fails To Meet Trial Primary Endpoint
January 3, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (AFX) - Biopharmaceutical company Evolutec Group PLC said it will stop investing in its rEV131 product after it failed to its primary endpoint in its Phase II post-cataract inflammation trial.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Huntington’s disease
PTC Nosedives Despite Claiming Phase II Win for Huntington’s Hopeful
May 5, 2025
·
2 min read
·
Dan Samorodnitsky
Policy
HHS To Require Placebo-Controlled Trials for All New Vaccines in ‘Radical Departure’ From Past
May 1, 2025
·
3 min read
·
Heather McKenzie
Multiple sclerosis
Immunic Talks Up Disability Gains as Phase II MS Therapy Fails on Primary Endpoint
May 1, 2025
·
2 min read
·
Tristan Manalac
Cancer
AACR 2025 Tracker: Merck, GSK, Roche and More Present Key Data
April 30, 2025
·
8 min read
·
BioSpace Editorial Staff
